Sagimet Biosciences (SGMT) Stock Overview
A clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
SGMT Community Fair Values
Create NarrativeSee what 16 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Sagimet Biosciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.32 |
| 52 Week High | US$11.41 |
| 52 Week Low | US$1.73 |
| Beta | 3.44 |
| 1 Month Change | -13.36% |
| 3 Month Change | -20.24% |
| 1 Year Change | 29.13% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -66.65% |
Recent News & Updates
Sagimet's Denifanstat: China Phase III Safety Data Isn't A Negative Signal
Jan 30We're Hopeful That Sagimet Biosciences (NASDAQ:SGMT) Will Use Its Cash Wisely
Jan 12
Recent updates
Sagimet's Denifanstat: China Phase III Safety Data Isn't A Negative Signal
Jan 30We're Hopeful That Sagimet Biosciences (NASDAQ:SGMT) Will Use Its Cash Wisely
Jan 12Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans
Mar 19Sagimet Biosciences' Denifanstat Should Be Worth More Today
Mar 07Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans
Dec 15Sagimet: More Than Just A MASH Drug Development Biotech
Nov 14Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat
Oct 18Sagimet Biosciences' Denifanstat Remains A Strong Buy Despite Eli Lilly's Tirzepatide
Jul 31Companies Like Sagimet Biosciences (NASDAQ:SGMT) Are In A Position To Invest In Growth
May 31Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity
Apr 26Sagimet: Additional Upside Possible After Latest NASH Data Release
Jan 24Shareholder Returns
| SGMT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.1% | 1.0% | 1.0% |
| 1Y | 29.1% | 26.2% | 14.6% |
Return vs Industry: SGMT exceeded the US Biotechs industry which returned 26.2% over the past year.
Return vs Market: SGMT exceeded the US Market which returned 14.6% over the past year.
Price Volatility
| SGMT volatility | |
|---|---|
| SGMT Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SGMT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SGMT's weekly volatility has decreased from 14% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 14 | Dave Happel | www.sagimet.com |
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs, such as various solid tumor and glioblastoma.
Sagimet Biosciences Inc. Fundamentals Summary
| SGMT fundamental statistics | |
|---|---|
| Market cap | US$173.01m |
| Earnings (TTM) | -US$57.67m |
| Revenue (TTM) | n/a |
Is SGMT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SGMT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$57.67m |
| Earnings | -US$57.67m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.77 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SGMT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/22 05:41 |
| End of Day Share Price | 2026/02/20 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sagimet Biosciences Inc. is covered by 12 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Eliana Merle | Barclays |
| Edward Nash | Canaccord Genuity |
| Jonathan Wolleben | Citizens JMP Securities, LLC |